

FOI REF: 23/757

15<sup>th</sup> November 2023

Eastbourne District General Hospital

Kings Drive  
Eastbourne  
East Sussex  
BN21 2UD

Tel: 0300 131 4500

Website: [www.esht.nhs.uk](http://www.esht.nhs.uk)

## FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

**Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.**

### PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML):

1) How many patients with AML, in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?

- |  |    |
|--|----|
| • Azacitidine monotherapy.                 | 1  |
| • Low dose cytarabine (LoDAC) monotherapy. | 1  |
| • Venetoclax + azacitidine.                | 17 |
| • Venetoclax + LoDAC.                      | 2  |
| • Ivosidenib.                              | 0  |
| • Intensive chemotherapy-based regimen.    | 11 |
| • Other.                                   | 71 |

2) How many newly diagnosed patients with AML have started first-line treatment with the following therapies during the last 6 months?

- |  |    |
|--|----|
| • Azacitidine monotherapy.                 | 0  |
| • Low dose cytarabine (LoDAC) monotherapy. | 0  |
| • Venetoclax + azacitidine.                | 10 |
| • Venetoclax + LoDAC.                      | 0  |
| • Ivosidenib.                              | 0  |
| • Intensive chemotherapy-based regimen.    | 6  |
| • Other                                    | 0  |

**Note: this should only include patients who have started first-line treatment during the 6-month window.**

Cont.../

- 3) (a) Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many are approved for treatment via Blueteq?

19.

**PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL):**

- 4) How many patients with CLL have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

7.

**Note: this should include patients who started treatment prior to the 6-month window.**

- 5) How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)?

1.

**Note: this should include only patients who have started treatment during the 6-month window.**

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department ([esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Linda Thornhill (Mrs)  
Corporate Governance Manager  
[esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)